Prognostic value of the baseline circulating T cell receptor β chain diversity in advanced lung cancer
Jiaqi Wang, Zhixin Bie, Yajing Zhang, Lin Li, Yujie Zhu, Yi Zhang, Xin Nie, Ping Zhang, Gang Cheng, Xuebing Di, Xiaoguang Li, Shujun Cheng, Lin Feng
Abstract
= .00083) in LUAD patients receiving targeted therapy. Higher baseline circulating TCRB diversity was associated with better prognosis. In addition, a five-factor prognostic risk score model was built for more accurate prognosis prediction for LUAD patients. The chemotherapeutic agents for advanced lung cancer do not significantly affect adaptive immune function over the first few treatment cycles. The circulating TCRB diversity reflects the adaptive immunological repertoire and might be a convenient indicator for evaluating the adaptive immune status and prognosis.
Topics & Concepts
MedicineLung cancerImmune systemImmunologyOncologyAcquired immune systemCancerInternal medicineCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune Cell Function and Interaction